50 Big Debates in Gynecologic Oncology

Section I: Perioperative Management
1A. Should routine mechanical bowel preparation be performed before primary debulking surgery? Yes Lea A. Moukarzel and Oliver Zivanovic
1B. Should routine mechanical bowel preparation be performed before primary debulking surgery? No Shannon Armbruster and Fidel A. Valea
2A . Should preoperative carbohydrate loading be routine prior to debulking surgery? Yes Arwa Mohammad, Deepa Maheswari M. Narasimhulu and Sean C. Dowdy
2B. Should preoperative carbohydrate loading be routine prior to debulking surgery? No Kathryn Miller, Dib Sassine and Yukio Sonoda
Section II: Screening, Prevention and Early Diagnosis
3A. Should women with BRCA mutations be offered bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction? Yes Thomas Boerner and Kara Long Roche
3B. Should women with BRCA mutations be offered bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction? No Steven A. Narod
4A. Can high-risk HPV testing be used alone as the primary screening modality for cervical cancer? Yes Thomas C. Wright
4B. Can high-risk HPV testing be used alone as the primary screening modality for cervical cancer? No Ibraheem O. Awowole and Olusegun O. Badejoko
Section III: Ovarian Cancer
5A. Should CA-125 surveillance be performed after completion of primary treatment for ovarian cancer patients in remission? Yes Eseohi Ehimiaghe and Edward Tanner
5B. Should CA-125 surveillance be performed after completion of primary treatment for ovarian cancer patients in remission? No Gordon J. S. Rustin
6A. In patients with BRCA-negative and HRD-negative epithelial ovarian cancer, should molecular profiling be routinely done to guide adjuvant therapy? Yes Ilaria Betella and Matteo Repetto
6B. In patients with BRCA-negative and HRD-negative epithelial ovarian cancer, should molecular profiling be routinely done to guide adjuvant therapy? No Raanan Alter and Ernst Lengyel
7A. Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse? Yes Rachel N. Grisham
7B. Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse? No David M. Gershenson
8A. Should Stage IC mucinous ovarian carcinoma be managed by observation or adjuvant chemotherapy? Observation Jason D. Wright
8B. Should Stage IC mucinous ovarian carcinoma be managed by observation or adjuvant chemotherapy? Adjuvant chemotherapy Jonathan Ledermann and Sophia Wong
9A. How many cycles of adjuvant chemotherapy should be administered to patients with high-risk Stage I epithelial ovarian cancer? Three cycles Annalisa Garbi, Eleonora Zaccarelli and Federica Tomao
9B. How many cycles of adjuvant chemotherapy should be administered to patients with high-risk Stage I epithelial ovarian cancer? Six cycles John K. Chan and Daniel S. Kapp
10A. Patients with advanced ovarian cancer who are 75 years old and older should routinely be treated withneoadjuvant chemotherapy: Yes Michelle Davis and Ursula Matulonis
10B. Patients with advanced ovarian cancer who are 75 years old and older should routinely be treated with neoadjuvant chemotherapy: No Olga T. Filippova and William P. Tew
11A. Should an attempt at aggressive cytoreduction be made for all surgical candidates with advanced ovarian cancer prior to treatment with adjuvant chemotherapy? Yes Sven Mahner, Anca Chelariu-Raicu and Fabian Trillsch
11B. Should an attempt at aggressive cytoreduction be made for all surgical candidates with advanced ovarian cancer prior to treatment with adjuvant chemotherapy? No Sean Kehoe and Jason Yap
12A. Should minimally invasive modalities be routinely/uniformly utilized for assessment of resectability prior to attempted primary debulking in patients with advanced ovarian cancer? Yes Juliet E. Wolford

Highlighting over 50 hot topics where controversy exist in management of patients with gynecologic malignancy, this book presents expertly argued opinions for and against, incorporating current evidence and clinical trials outcomes. A diverse range of topics are included that pertain to several disciplines in gynecologic oncology, including surgical management of disease, medical oncology, immunotherapy, radiation therapy, as well as screening, preventive and palliative care. This book will be relevant to a diverse audience of practitioners and trainees including gynecologists, gynecological oncologists, surgeons, medical oncologists, radiation oncologists, and general medics. It will be a useful guide for practicing clinicians managing their patients, as well as a concise textbook for trainees and students preparing for examinations and board certifications in gynecologic oncology. Readers will gain an insight into topical controversies, critically evaluating the different sides to enhance their own clinical practice.

Dennis S. Chi, Memorial Sloan-Kettering Cancer Center, New York
Dennis S. Chi is the Ronald O. Perelman Chair in Gynecologic Surgery, Deputy Chief of the Gynecology Service, and Head of Ovarian Cancer Surgery at Memorial Sloan Kettering Cancer Center, New York, NY.

Nisha Lakhi, Richmond University Medical Center, Staten Island
Nisha Lakhi is the Senior Director of Clinical Oncology and Director of Research at Richmond University Medical Center, Staten Island, NY. She lead her institution's Cancer Program with special emphasis on gynecologic oncology and cancer survivorship and recently received the national “40 under 40 Cancer Award (2019)”.

Nicoletta Colombo, University of Milan-Bicocca
Nicoletta Colombo is Professor of Gynecological Oncology, University of Milan-Bicocca. She was President of ESGO from 2011-2013, chair of the ESMO-ESGO-ESP consensus Conference on endometrial Cancer in 2016 and Chair of ESMO-ESGO Ovarian Cancer Consensus Conference in 2019. She is chair elect of ENGOT (2022-2024).